GynecologyGynecology2079-56962079-5831Consilium Medicum27951Research ArticleLechenie menopauzal'nykh rasstroystv pri nalichii riska giperplazii endometriya u zhenshchin s izbytochnoy massoy telaKuznetsovaI V-YakokutovaM V-15082008104464909042020Copyright © 2008, Consilium Medicum2008климактерический синдромгиперплазия эндометрияизбыточная масса телаожирение[Серов В.Н. Гинекологическая эндокринология. 1998; 358.][Blumel J.L, Cruz M.N, Aparicio N.J. Menopausal travsition, physiopathology, clinical and treatment. Medicina (B – Aries) 2002; 62 (1): 57–65.][Mattews D, Hosker J, Rudenski A et al. Homeostasis model asessment: insulin resistance and b - cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412–9.][Clinician`s Manual on Total Risk Management. A guide to prevention of Coronary Heart Disease. Science Press Ltd and Society of Cardiology, 2000.][Trigatti B.L, Krieger M, Rigotti A. Influence of the HDL receptor SRB-1 on lipoprotein metabolism and atherosclerosis. Arterioscler Tromb Vasc Biol 2003; 23: 1732–8.][Koh K.K, Jin D.K, Yang S.H et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Crculation 2001; 103: 1961–6.][Gobsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentration: analysis of studies published from 1974–2000. Fertil Steril 2001; 75 (5): 898–915.][Jansen H, Verhoeven A.J.M, Sijbrands J.G. Hepatic lipase: a pro - or anti - atherogenic protein? J Lipid Research 2002; 43: 1352–62.][Kwok S, Selby P.L, Mc Elduff P et al. Progestogens of varying androgenecity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol 2004; 61: 760–7.][Kalish M.K, Barret-Connor E, Laughlin G.A, Gulansky B.I. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88 (4): 1646–52.][Rosano G.M.C, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in postmenopausal women: implications for cardioprotection. Maturitas 2003; 46 (S1): 17–29.][Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпрессинформ, 2004.][Yasui T, Umino Y, Takikawa M et al. Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index. Menopause 2005; 12 (2): 223–31.][Rubig A. Drospirenone, a new cardiovascular - active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6 (Suppl. 3): 49–54.][Григорян О.Р. Влияние препарата "Фемостон 1/5" на композиционный состав тела у женщин с сахарным диабетом 2 типа в период постменопаузы. Ожирен. и метабол. 2004; 2: 30–34.][Van de Weijer P.H.M, Scholten P, van de Mooren M.J et al. Bleeding patterns and histology during administration of low dose estradiol sequentially combined with dydrogesterone. Cimacteric 1999; 2: 1–9.]